What non‑CPAP treatment options are appropriate for a patient with sarcoidosis who cannot use a mask and whose insurance denies coverage for an implantable hypoglossal nerve stimulator?

Mandibular Advancement Device (MAD) is Your Best Option

For this patient with sarcoidosis and OSA who refuses mask therapy and cannot access hypoglossal nerve stimulation, I strongly recommend a custom-made dual-block mandibular advancement device (MAD) as the primary treatment. 1

Treatment Algorithm

First-Line: Mandibular Advancement Device

• Custom-made dual-block MAD is the most appropriate non-CPAP, non-implantable option with established efficacy 1, 2
• Most effective in mild-to-moderate OSA, but can still provide benefit in severe cases 2
• Requires dental evaluation to ensure adequate dentition and no temporomandibular joint disorders
• Success rates improve with drug-induced sleep endoscopy (DISE) to assess collapse patterns 2

Second-Line Considerations

Positional Therapy (if OSA is position-dependent):

• Use if supine AHI is significantly higher than lateral AHI
• Modern devices provide vibrotactile feedback to prevent supine sleeping 1

Myofunctional Therapy:

• Can be added as adjunctive treatment
• Involves oropharyngeal exercises to strengthen upper airway muscles 1, 2
• Requires 6-12 weeks of consistent practice

Surgical Options (if MAD fails)

Maxillomandibular Advancement (MMA):

• Most effective surgical option after hypoglossal nerve stimulation
• Appropriate for severe OSA when other options fail 1, 2
• Requires craniofacial surgery consultation

Upper Airway Surgery:

• Patient selection critical—DISE essential to identify collapse sites 2
• Success depends on anatomic phenotype

Critical Sarcoidosis Considerations

The sarcoidosis diagnosis requires specific attention:

• Ensure pulmonary sarcoidosis is adequately treated per ERS guidelines 3
• If symptomatic pulmonary involvement exists, glucocorticoids ± methotrexate should be optimized first 3
• Untreated pulmonary sarcoidosis can worsen OSA and complicate treatment outcomes
• Fatigue from sarcoidosis may overlap with OSA symptoms—consider pulmonary rehabilitation 3

Common Pitfalls to Avoid

1. Don't assume all non-CPAP options are equally ineffective—MAD has robust evidence 1
2. Don't skip DISE before surgical interventions—it significantly improves surgical success rates 2
3. Don't ignore the sarcoidosis—active disease may require immunosuppression that takes priority 3
4. Don't overlook weight management—even modest weight loss improves OSA severity 2

Insurance Appeal Strategy

While pursuing MAD, document CPAP failure thoroughly and consider appealing the hypoglossal nerve stimulator denial with:

• Documented CPAP intolerance/refusal
• Severity of OSA (AHI, oxygen desaturation)
• Impact on quality of life and cardiovascular risk
• MAD trial outcomes if suboptimal

The evidence shows hypoglossal nerve stimulation achieves ~68% AHI reduction with 70% decrease in oxygen desaturation at 12 months 4, making it worth pursuing if MAD proves insufficient.